Asitri Dashboard

Search Clinical Trials

The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.

Saved Searches

Choose Search
Basic Search
Targeted Search

Clinical Trials Search Results

Search History:
Count: 95
Selected: 0
NCT IDTitle
NCT04984330Selinexor for Treatment of Light Chain Amyloidosis With Relapsed/Refractory Disease
NCT02471911KPT-330 Plus RICE for Relapsed/Refractory Aggressive B-Cell Lymphoma
NCT02303392Selinexor and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Aggressive Non-Hodgkin Lymphoma
NCT04562389Study of Selinexor in Combination With Ruxolitinib in Myelofibrosis
NCT03627403Selinexor in Myelofibrosis Refractory or Intolerant to JAK1/2 Inhibitors
NCT02741388A Phase Ib Study of Oral Selinexor in Adult Patients With Relapsed/Refractory B-cell Lymphoma Receiving R-DHAOx or R-GDP
NCT03193437Selinexor in Patients With Advanced Thymic Epithelial Tumor Progressing After Primary Chemotherapy
NCT07362225MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, and Disease Progression in People With Myeloproliferative Neoplasms (MPNs)
NCT02025985Study of KPT-330 (Selinexor) in Female Patients With Advanced Gynaecologic Malignancies
NCT04349098Evaluation of Activity and Safety of Oral Selinexor in Participants With Severe COVID-19 Infection
NCT02780609Selinexor Plus High-Dose Melphalan (HDM) Before Autologous Hematopoietic Cell Transplantation for Multiple Myeloma
NCT04843579Treatment of Selinexor in Combination With Clarithromycin, Pomalidomide and Dexamethasone for Relapsed Refractory Multiple Myeloma Patients
NCT01986348Study Evaluating the Efficacy and Safety of Selinexor (KPT-330) in Participants With Recurrent Gliomas
NCT02213133Selinexor Treatment of Advanced Relapsed/Refractory Squamous Cell Carcinomas
NCT03880123Selinexor in Combination With Ixazomib for the Treatment of Advanced Sarcoma
NCT03732703Myeloma-Developing Regimens Using Genomics (MyDRUG)
NCT02227251Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
NCT03042819Study of Selinexor and Doxorubicin in Advanced Soft Tissue Sarcomas
NCT02250885KPT-330 to Treat Poorly Differentiated Lung and Gastroenteropancreatic Tumors
NCT02138786Selinexor in Initial or Refractory and/or Relapsed Richter's Transformation
NCT06399640Eltanexor and Venetoclax in Relapsed or Refractory Myelodysplastic Syndrome and Acute Myeloid Leukemia
NCT02530476Phase I/II, Study of Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) + Sorafenib in Acute Myeloid Leukemia
NCT04856189Selinexor and Pembrolizumab for the Treatment of Cisplatin-Ineligible or Cisplatin-Refractory Locally Advanced or Metastatic Urothelial Carcinoma
NCT02389543Study of Selinexor (KPT- 330), Lenalidomide, & Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients
NCT04925193Personalized Selinexor-based Therapy for Relapsed/Refractory Multiple Myeloma
NCT02212561Selinexor With Fludarabine and Cytarabine for Treatment of Refractory or Relapsed Leukemia or Myelodysplastic Syndrome
NCT07832227Imlunestrant/Abemaciclib/Selinexor in Ovarian and Endometrial
NCT01896505A Phase I Trial to Assess the Effects of Food and Formulation on PK of KPT-330 in Patients With Sarcoma
NCT02186834Selinexor (KPT-330) and Liposomal Doxorubicin For Relapsed and Refractory Multiple Myeloma
NCT04256707Relative Bioavailability/Bioequivalence of Different Formulations of Selinexor, the Impact of Hepatic Impairment on Selinexor Pharmacokinetics, Tolerability and Antitumor Activity of Selinexor Combination Treatment
NCT05177276Selinexor Combination Ph 1 Study
NCT02416908Study of CLAG + Selinexor in Relapsed or Refractory Acute Myeloid Leukemia
NCT03071276Selinexor in Combination With Fludarabine and Cytarabine in Patients With Refractory or Relapsed Acute Myeloid Leukemia
NCT07215832Karyopharm Expanded Access Program for Selinexor
NCT07200102Selinexor Maintenance Post CAR-T Cell Therapy for Multiple Myeloma
NCT04782687Study of Selinexor Plus DRd for Newly Diagnosed Multiple Myeloma
NCT02336815Selinexor Treatment of Refractory Myeloma
NCT04717700Selinexor With Alternating Bortezomib or Lenalidomide Plus Dexamethasone in TIE Newly Diagnosed MM Patients
NCT07447817Selinexor and Pacritinib in JAK Inhibitor-naïve MF Patients With Cytopenias
NCT01607905Safety Study of KPT-330 (Selinexor) in Patients With Advanced or Metastatic Solid Tumor Cancer
NCT02402764Phase 2 Trial of Selinexor (KPT-330) for Metastatic Triple Negative Breast Cancer (TNBC)
NCT02120222Evaluating SINE KPT-330 in Treating Patients With Melanoma That Cannot Be Removed By Surgery
NCT03191981Pembrolizumab Cyclophosphamide and Lenalidomide for Patients With Relapsed Multiple Myeloma
NCT04421378A Study of Selinexor in Combination With Standard of Care Therapy for Newly Diagnosed or Recurrent Glioblastoma
NCT02831686A Study to Test the Combination of Selinexor (KPT-330), Ixazomib, and Dexamethasone in Patients With Myeloma
NCT02299518Selinexor and Chemotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
NCT03095612Phase 1/2 Trial of Selinexor (KPT-330) With Docetaxel for Non-small Cell Lung Cancer (NSCLC)
NCT02078349Phase I Study of KPT330 in Asian Patients
NCT04661137A Study of Selinexor, in Combination With Carfilzomib, Daratumumab or Pomalidomide in Patients With Multiple Myeloma
NCT02228525Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) in Patients With Myelodysplastic Syndromes